Warberg Asset Management’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Warberg Asset Management’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-55,000	Closed	-$21K	–	335
2022 Q2	$21K	Buy	+55,000	New	+$38.5K	﹤0.01%	183

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Warberg Asset Management's CRXT Position: Q3 2022 in Review

Warberg Asset Management sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 55,000 shares — an estimated $21K sold.

Warberg Asset Management first reported a position in CRXT in Q2 2022 and held it in 1 quarter. The position peaked at $21K in Q2 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

Warberg Asset Management reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Warberg Asset Management sold 55,000 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $21K.
Warberg Asset Management first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Warberg Asset Management's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $21K in Q2 2022.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Warberg Asset Management's 13F filing for Q3 2022, filed 7 Nov 2022.